Our cells rely on tightly regulated signaling pathways to control when they grow, divide and survive. When these regulatory ...
For (adult) patients with relapsed or refractory chronic lymphocytic leukemia (CLL), a new line of treatment has been ...
Series B proceeds will fund clinical proof-of-biology studies of SARM1 inhibitors– First patient dosed in Phase 1b/2a ALS study with NB-4746, ...
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...
Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive results from the Phase III Krascendo 1 study evaluating divarasib, an investigational next-generation KRAS ...
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus ...
Everest Medicines, a Shanghai-based biopharmaceutical company listed on the Hong Kong Stock Exchange, announced the closing ...
Which Is a Better Investment, Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. Stock?
Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...
Roche announces positive result in Phase III trial of cancer drug divarasib: Basel Friday, July 3, 2026, 17:00 Hrs [IST] Roche announced positive results from the phase III Krasce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results